Literature DB >> 2178870

Tenoxicam compared with diclofenac in patients with ankylosing spondylitis.

A C Schwarzer1, M Cohen, M H Arnold, D Kelly, P McNaught, P M Brooks.   

Abstract

A randomized study was performed on 24 patients with ankylosing spondylitis to compare the efficacy and tolerability of 20 mg tenoxicam daily with 50 mg diclofenac twice daily. There were 6 withdrawals from the group taking tenoxicam and 4 from the diclofenac group. Depression in 1 patient taking tenoxicam was the only significant adverse event. Both drugs were otherwise well tolerated. Tenoxicam and diclofenac were rated as good or excellent by 27% and 55% of patients, respectively. Global assessment, pain and duration of morning stiffness were improved with both drugs but this improvement was not statistically significant and there was no statistically significant difference between the two groups. This study confirms that tenoxicam is effective and well tolerated but larger numbers would be required to detect a small difference between groups.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178870     DOI: 10.1185/03007999009112691

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  8 in total

Review 1.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 2.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

Review 3.  Ankylosing spondylitis: an overview.

Authors:  J Sieper; J Braun; M Rudwaleit; A Boonen; A Zink
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 4.  Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

5.  Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis.

Authors:  Ricardo da Cruz Lage; Claudia Diniz Lopes Marques; Thauana Luiza Oliveira; Gustavo Gomes Resende; Charles Lubianca Kohem; Carla Gonçalves Saad; Antônio Carlos Ximenes; Célio Roberto Gonçalves; Washington Alves Bianchi; Eduardo de Souza Meirelles; Mauro Waldemar Keiserman; Adriano Chiereghin; Cristiano Barbosa Campanholo; André Marun Lyrio; Cláudia Goldenstein Schainberg; Lenise Brandao Pieruccetti; Michel Alexandre Yazbek; Penelope Esther Palominos; Rafaela Silva Guimarães Goncalves; Rodrigo Luppino Assad; Rubens Bonfiglioli; Sônia Maria Alvarenga Anti Loduca Lima; Sueli Carneiro; Valderílio Feijó Azevedo; Cleandro Pires Albuquerque; Wanderley Marques Bernardo; Percival Degrava Sampaio-Barros; Marcelo de Medeiros Pinheiro
Journal:  Adv Rheumatol       Date:  2021-01-19

Review 6.  Pharmacological treatment of ankylosing spondylitis: a systematic review.

Authors:  Pauline Boulos; Maxime Dougados; Stuart M Macleod; Elke Hunsche
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Efficacy of diclofenac/misoprostol vs diclofenac in the treatment of ankylosing spondylitis.

Authors:  F McKenna
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 8.  Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).

Authors:  Féline P B Kroon; Lennart R A van der Burg; Sofia Ramiro; Robert B M Landewé; Rachelle Buchbinder; Louise Falzon; Désirée van der Heijde
Journal:  Cochrane Database Syst Rev       Date:  2015-07-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.